(Total Views: 893)
Posted On: 07/07/2020 3:23:54 PM
Post# of 153887
BP's manuscript will be submitted to respected scientific journal and is not a clinical trial, a very different process of review. His science and statistical analysis is perfect. I have read the manuscript 10 times trying to blow holes in it and could not find one. I have communicated with BP. His request for a patent on an assay for rantes is also telling. I just wish I could invest in INTELDX, but it could be an attractive IPO especially my financial house gabs a significant position at the bell.
By the way since there quite an interest in COVID, look into Aperion in Austria, no ADR yet. Since American Regents is a subsidiary of Daiiishki
(on it;s way to their goal to becoming THE largest company in Japan) there could be a joint operating agreement in the future.
It is a monster company with projected stock price to go up significantly and has and ADR, which is publicly traded in the US.
By the way since there quite an interest in COVID, look into Aperion in Austria, no ADR yet. Since American Regents is a subsidiary of Daiiishki
(on it;s way to their goal to becoming THE largest company in Japan) there could be a joint operating agreement in the future.
It is a monster company with projected stock price to go up significantly and has and ADR, which is publicly traded in the US.
(3)
(0)
